#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Glioma Thrombocytosis Antisynthetase syndrome Bronchopulmonary aspergillosis Mucous membrane pemphigoid Solitary fibrous tumour Round cell liposarcoma Eosinophilic oesophagitis Hypomagnesaemia Hepatoblastoma Marfan's syndrome Acute myeloid leukaemia recurrent T-cell lymphoma Mantle cell lymphoma recurrent Hypochromic anaemia More trials…

    Learn about Rare Diseases

    Haemophilia A with anti factor VIII – Diagnostics Retinoblastoma – Life with Disease Haemophagocytic lymphohistiocytosis – Life with Disease Congenital nephrogenic diabetes insipidus – Life with Disease Glomerulonephritis membranous – Life with Disease Angiosarcoma metastatic – Life with Disease Factor VIII deficiency – Diagnostics Von Willebrand’s disease – Basic Information X-linked lymphoproliferative syndrome – Life with Disease Glycogen storage disease type V – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Donanemab TALADEGIB Gsk4381562A Diltiazem Hydrochloride Disulfiram KETOROLAC SARACATINIB Ecubectedin Cholesterol Tpst-1120 HYPOCHLOROUS ACID Pemafibrate Spartalizumab Tovinontrine Guanabenz Acetate Gs-5245 Dexamethasone Phosphate Gsk6097608 Rmc-6291 Metyrapone More therapies…

    Learn about Your Condition

    Peritoneal abscess Chronic hepatitis C Menopause Spermatocele Deafness neurosensory Biliary neoplasm Fallopian tube cancer Abdominal pain Thalassaemia beta Thyroid disorder Raynaud's phenomenon Alopecia areata Ovarian cancer metastatic Migraine Langerhans' cell histiocytosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Prostate cancer metastatic

  • Study of Darolutamide and Testosterone for Patients with Advanced Prostate Cancer Resistant to Standard Hormone Therapy

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Testosterone
    • Abiraterone
    • Darolutamide
    Germany

  • Study Comparing Ifinatamab Deruxtecan and Docetaxel for Patients with Advanced Prostate Cancer Resistant to Hormone Therapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Betamethasone Sodium Phosphate
    • Buclizine Hydrochloride
    • Codeine Phosphate
    Austria Czechia Denmark France Germany Greece +7

  • Study on Re-treatment with Lutetium (177Lu) Vipivotide Tetraxetan for Men with Metastatic Castration-Resistant Prostate Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    Investigated Drugs:
    • Lutetium (177Lu) Vipivotide Tetraxetan
    • Gozetotide
    France

  • Study on the Effect of Degarelix on Prostate-Specific Membrane Antigen in Patients with Untreated Metastatic Prostate Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    • Prostate cancer
    Investigated Drugs:
    • Degarelix
    Finland

  • Study of PF-06821497 and Enzalutamide for Men with Advanced Prostate Cancer Resistant to Hormone Therapy

    Recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • 5,8-Dichloro-2-[(4-Methoxy-6-Methyl-2-Oxo-1,2-Dihydropyridin-3-Yl)Methyl]-7-[(R)-Methoxy(Oxetan-3-Yl)Methyl]-3,4-Dihydroisoquinolin-1(2H)-One
    • Enzalutamide
    Bulgaria Czechia Denmark Finland France Germany +8

  • Study of 177Lu-PSMA and Stereotactic Radiotherapy vs. Radiotherapy for Patients with Oligometastatic Prostate Cancer

    Recruiting

    2 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    Investigated Drugs:
    • 177LU-PSMA-I&T
    Italy
Previous Page
1 2 3 4 … 8
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!